Health Policy Newsletter

Volume 21 • Number 1

March 2008

The Missing PEACE of the Puzzle
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In recent years, medication costs have been rising at alarming rates, leaving hospitals in
search of ways to control pharmaceutical spending. Typically, a hospital's Pharmacy and
Therapeutics (P&T) committee would lead this process; however, this task becomes a
greater challenge at larger institutions. Here at Thomas Jefferson University Hospital
(TJUH), we’ve found another way to combat rising drug costs – through the
PharmacoEconomics and Clinical Effectiveness (PEACE) committee. PEACE has undertaken the charge to achieve quality outcomes while optimizing dollars spent.1, 2
PEACE was established by hospital administration in 2003 with the goal of addressing
high cost and high volume medications and disease states. It runs parallel to the P&T
Committee, and reports directly to hospital administration. In contrast, the P&T committee
reports to the medical executive committee. Members of the committee include the
Chief Medical Officer, the Chief Financial Officer, administrative representatives from the
pharmacy and nursing departments, and the medical staff. The PEACE committee,
through various benchmarking reports and internal analysis, identifies items that
match the committee’s goals. Following data collection and discussion, PEACE then
forwards the analysis to the appropriate P&T subcommittee for further insight and
guideline development.
One of the first undertakings of the PEACE committee was to address the use of
erythropoesis-stimulating agents (ESAs). Erythropoetin is a high cost medication used
for red blood cell stimulation in patients with anemia. Given that the cost of this
medication was greater than any other at the time, it became one of the committee's
first projects. After identifying committee members with expertise in the area and
gathering information from other institutions, PEACE chose the most appropriate agent
from the class and developed evidence-based guidelines for the medication. The
outcome was savings amounting to greater than half a million dollars per year.
Within the past year, the committee began to address the nationwide increase of a
potentially life-threatening infection, Clostridium difficile (C. diff ). While the effort had
very little to do with financial implications, it focused on another of the committee's key
goals: optimizing appropriate patient care. Recent literature suggests risk factors for

C. diff may include the use of broad spectrum antibiotics (BSAs) in combination with
gastric acid suppressants (GASs), which include proton pump inhibitors (PPIs) like
esomeprazole or H2 antagonists like famotidine.3, 4 Although much attention has been
given to BSAs, it is equally important to focus on the GASs. The committee learned that
62% of TJUH patients were receiving one of these agents, with the PPI group comprising
greater than three-quarters of the use. When benchmarked against use of PPIs in other
University HealthSystem Consortium (UHC) hospitals, use at TJUH was double that of
other similarly sized institutions.
PEACE committee representatives worked with the Gastroenterology subcommittee
of the P&T Committee to develop an action plan to effectively decrease unnecessary
use of GASs. A three-step procedure was designed, and is now in various stages of
implementation. It includes education to all medical staff, an alert indicating when a
GAS is being ordered for a patient already on a BSA, and lastly, a stricter ordering
process for these medications. The impact of these actions is still under evaluation;
however, early data shows a 6% decrease in PPI use in the past quarter.
Since its inception, PEACE has addressed numerous topics, including topical thrombin,
inhaled nitric oxide, and chemotherapy. The committee continues to show promising
results in meeting its charge to optimize patient care in a cost-effective manner.
The examples provided in this article are surely just the beginning of PEACE’s role in
positively impacting patient care at TJUH.
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